This content has not yet been reviewed and may contain errors.

approach to elevated liver enzymes

in review 4 min read Updated 2026-08-18
Contents
approach to elevated liver enzymes

Classify the pattern first: hepatocellular (ALT/AST dominant) vs cholestatic (ALP/GGT dominant) vs mixed. The magnitude of transaminase elevation narrows the differential substantially. Cholestatic patterns split by whether bile ducts are dilated on imaging. A systematic first-pass panel catches the majority of causes without shotgun testing.

do not miss
  • transaminases >1000 U/L → acute liver injury (toxin, ischaemia, acute viral) — identify cause and trend within hours
  • rising bilirubin with falling albumin or rising INR → synthetic failure — hepatology urgently
  • encephalopathy → this is acute liver failure, not just “elevated enzymes”
  • new ascites or signs of portal hypertension

pattern recognition

hepatocellular (ALT/AST dominant)

magnitudedifferential
>1000 U/L (“thousands”)toxins/drugs (acetaminophen, cocaine), acute viral hepatitis (A, B, D, E), ischaemic hepatitis (shock liver), Budd-Chiari syndrome, acute biliary obstruction (<24 h), autoimmune hepatitis, fulminant Wilson’s disease
100–1000 U/L (“hundreds”)chronic viral (HBV, HCV, EBV, CMV), congestive hepatopathy, alcohol-associated hepatitis (AST > ALT, ratio ≥1.5–2:1, values <400 U/L)
<100 U/LMASLD/MetALD, celiac disease, hereditary hemochromatosis, Wilson’s disease, alpha-1 antitrypsin deficiency, hypothyroidism
AST:ALT ratio

AST > ALT with ratio ≥2:1 and both values <400 U/L → alcohol-associated liver disease until proven otherwise. The ratio reflects mitochondrial injury from alcohol plus pyridoxine deficiency lowering ALT. An AST:ALT ratio >1 in someone with chronic hepatitis also raises concern for advancing fibrosis/cirrhosis.

cholestatic (ALP/GGT dominant)

Extrahepatic (bile duct dilatation on US/MRCP):

  • painful → choledocholithiasis
  • painless → strictures (PSC, benign, IgG4-related disease) or malignancy (cholangiocarcinoma, pancreatic head, ampullary)

Intrahepatic (no duct dilatation):

  • drugs (antibiotics, TPN, oestrogens, methotrexate)
  • PBC
  • sepsis, cholestasis of pregnancy
  • infiltrative (sarcoidosis, amyloid, lymphoma)
  • metastatic disease
ERCP is therapeutic, not diagnostic

When cholestatic imaging is needed, use US first then MRCP. ERCP carries procedural risk (pancreatitis, perforation) and is reserved for therapeutic intervention — stone extraction, stent placement, stricture dilation.

isolated elevations

  • Isolated ALP elevation → confirm hepatic origin with GGT (if GGT normal, ALP is likely bone). In pregnancy, placental ALP rises physiologically.
  • Isolated GGT elevation → non-specific; alcohol, drugs, obesity, diabetes. Not useful in isolation as a screening test.
  • Isolated AST elevation → consider cardiac or skeletal muscle source (check CK). Macro-AST is a rare benign cause of persistent elevation.

first-pass workup

Order based on pattern, not as a reflex panel:

hepatocellularcholestaticboth patterns
hepatitis serologies (HAV IgM, HBsAg, anti-HBc, anti-HCV)abdominal US (duct dilatation?)CBC, INR, albumin, bilirubin
ferritin + transferrin saturationAMA (if intrahepatic pattern)lipase
ceruloplasmin (age <40)MRCP (if US equivocal or high suspicion for stones/stricture)pregnancy test (reproductive age)
ANA, ASMA, IgG (AIH screen)IgG4 (if stricture on imaging)drug/supplement review
alpha-1 antitrypsin levelabdominal US
tTG-IgA + total IgA (celiac)
do not forget the drug history

Medications, supplements, and herbal products are among the most common causes of elevated liver enzymes across all patterns. Statins cause mild transaminase elevation in up to 3% but rarely cause clinically significant liver injury — statin hepatotoxicity is massively over-diagnosed and should not prompt discontinuation unless ALT exceeds 5× ULN with symptoms.


traps

  • Assuming elevated ferritin = haemochromatosis — ferritin is an acute-phase reactant. Transferrin saturation <45% with normal ferritin rules out hereditary hemochromatosis with 97% NPV. No HFE testing needed.
  • Stopping statins for mild ALT elevation — check ALT was not already elevated before starting. Baseline MASLD is more common than statin hepatotoxicity.
  • Missing celiac disease — causes unexplained mild transaminase elevation in up to 9% of cases. Screen with tTG-IgA + total serum IgA.
  • Ordering ERCP for diagnosis — MRCP is the diagnostic study for biliary obstruction; ERCP is interventional.
  • Ignoring alcohol — patients underreport; AST:ALT ratio and GGT help. AUDIT-C is a reasonable screening tool.

related: viral hepatitis · alcohol-associated hepatitis · MASLD · hereditary hemochromatosis · autoimmune and metabolic liver diseases · cirrhosis · celiac disease

Key references